REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Deep Sleep Restoration

Sleep Optimizationbeginner
48
Share
Peptides

2

Avg Daily mcg

300

Level

beginner

Added

May 16, 2026

Overview

Deep Sleep Restoration is a beginner-level sleep optimization stack that pairs two well-tolerated peptides to enhance sleep depth, promote natural growth hormone release during rest, and support overnight physical recovery. This straightforward protocol is ideal for those new to peptide therapy who struggle with light or fragmented sleep. DSIP (Delta Sleep-Inducing Peptide) at 100mcg daily is a naturally occurring neuropeptide first isolated from rabbit cerebral venous blood during slow-wave sleep. It promotes entry into deep delta-wave sleep stages (NREM stages 3 and 4), which are critical for immune function, cellular repair, and memory consolidation. Unlike pharmaceutical sedatives, DSIP does not force unconsciousness—it facilitates the brain natural transition into restorative sleep phases. Research indicates DSIP normalizes disrupted sleep patterns and reduces sleep onset latency, particularly in individuals with stress-induced insomnia. At 100mcg, this conservative dose provides meaningful benefit while minimizing any adaptation. Ipamorelin at 200mcg daily is a selective growth hormone secretagogue that stimulates pulsatile GH release from the anterior pituitary. When administered before sleep, it amplifies the natural nocturnal GH surge that occurs during deep sleep. This enhanced GH output accelerates tissue repair, muscle recovery, and fat metabolism overnight. Ipamorelin is notably clean in its action—it does not significantly raise cortisol or prolactin, making it one of the best-tolerated GH peptides available. The synergy here is straightforward: DSIP deepens the sleep that triggers natural GH release, while Ipamorelin amplifies that release. The result is both better subjective sleep quality and enhanced physiological recovery during rest. Protocol Notes: Both peptides should be administered subcutaneously 30-60 minutes before bedtime on an empty stomach (no food for 2 hours prior, as insulin blunts GH release). This stack is well-suited for beginners, athletes seeking improved recovery, and anyone over 30 noticing declining sleep quality. Typical cycles run 4-8 weeks. Users commonly report deeper sleep within the first week, with progressive improvements in morning energy and recovery over the full cycle.

Dosing Protocol

100 mcg

per dose

200 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.